Aytu BioPharma Inc. reported its fiscal 2025 third quarter results, highlighting a strong performance with a 32% increase in total net revenue, reaching $18.5 million compared to $14.0 million in the same quarter of fiscal 2024. The company's ADHD Portfolio, including products such as Adzenys XR-ODT® and Cotempla XR-ODT®, experienced a 25% increase in net revenue, rising to $15.4 million from $12.3 million in the prior year's third quarter. The Pediatric Portfolio, featuring Karbinal® ER, Poly-Vi-Flor®, and Tri-Vi-Flor®, saw a significant 77% growth, with net revenue climbing to $3.1 million from $1.7 million. Net income for the quarter was reported at $4.0 million, or $0.65 basic and $0.21 diluted earnings per share, a notable turnaround from a net loss of $2.9 million, or $0.52 net loss per share, in Q3 fiscal 2024. Adjusted EBITDA also saw a substantial increase, reaching $3.9 million compared to $0.9 million in the previous year's third quarter. Additionally, Aytu BioPharma's cash and cash equivalents stood at $18.2 million as of March 31, 2025. The company remains committed to optimizing its commercial prescription infrastructure and is actively pursuing additional in-licensed or acquired products to enhance its CNS-focused sales capabilities and the Aytu RxConnect patient access platform.